Originally published as Genetics Published Articles Ahead of Print on June 18, 2008.

Genetics, Vol. 179, 1345-1355, July 2008, Copyright © 2008
doi:10.1534/genetics.108.088591

Relationship of Pax6 Activity Levels to the Extent of Eye Development in the Mouse, Mus musculus

* Institute of Human Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, D-85764 Neuherberg, Germany and {dagger} Centre National de la Recherche Scientifique, UMR 146, Institut Curie Section de Recherche, Centre Universitaire, 91405 Orsay Cedex, France

1 Corresponding author: Institute of Human Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstaedter Landstrasse 1, D-85764 Neuherberg, Germany.
E-mail: favor{at}helmholtz-muenchen.de

In this study we extend the mouse Pax6 mutant allelic series to include a homozygous and hemizygous viable hypomorph allele. The Pax6132-14Neu allele is a Phe272Ile missense mutation within the third helix of the homeodomain. The mutant Pax6 homeodomain shows greatly reduced binding activity to the P3 DNA binding target. Glucagon-promoter activation by the entire mutant Pax6 product of a reporter gene driven by the G1 paired and homeodomain DNA binding target was slightly increased. We constructed mutant Pax6 genotypes such that Pax6 activity ranged between 100 and 0% and show that the extent of eye development is progressively reduced as Pax6 activity decreased. Two apparent thresholds identify three groups in which the extent of eye development abruptly shifted from complete eye at the highest levels of Pax6 to a rudimentary eye at intermediate levels of Pax6 to very early termination of eye development at the lowest levels of Pax6. Of the two Pax6-positive regions that participate in eye development, the surface ectoderm, which develops into the lens vesicle and the cornea, is more sensitive to reduced levels of Pax6 activity than the optic vesicle, which develops into the inner and outer retinal layers.




This article has been cited by other articles:


Home page
IOVSHome page
M. Hingorani, K. A. Williamson, A. T. Moore, and V. van Heyningen
Detailed Ophthalmologic Evaluation of 43 Individuals with PAX6 Mutations
Invest. Ophthalmol. Vis. Sci., June 1, 2009; 50(6): 2581 - 2590.
[Abstract] [Full Text] [PDF]